Clostridium difficile-induced colitis in mice is independent of leukotrienes

Anaerobe

Volumn 30, Issue , 2014, Pages 90-98

  Trindade, Bruno C ^a,b   Theriot, Casey M ^c   Leslie, Jhansi L ^c   Carlson, Paul E ^c   Bergin, Ingrid L ^d   Peters Golden, Marc ^c   Young, Vincent B ^c   Aronoff, David M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b MINISTRY OF EDUCATION OF BRAZIL   (Brazil)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Clostridium difficile; Eicosanoid; Leukotriene; Nosocomial infection

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN B; CYTOKINE; IMMUNOGLOBULIN G ANTIBODY; LEUKOTRIENE; LEUKOTRIENE B4; PEPTIDOLEUKOTRIENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; EDEMA; FATTY ACID SYNTHESIS; FEMALE; HISTOLOGY; HOST SUSCEPTIBILITY; INFLAMMATION; INTESTINE; MOUSE; NEUTROPHIL; NONHUMAN; TISSUE INJURY; ANIMAL; C57BL MOUSE; CLOSTRIDIUM INFECTION; CYTOCHEMISTRY; DISEASE MODEL; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PATHOLOGY; PEPTOCLOSTRIDIUM DIFFICILE;

ANIMALS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS; DISEASE MODELS, ANIMAL; FEMALE; HISTOCYTOCHEMISTRY; LEUKOTRIENES; MICE, INBRED C57BL;

EID: 84907482434     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2014.09.006     Document Type: Article

References (58)

1. Depestel D.D., Aronoff D.M. Epidemiology of Clostridium difficile infection. JPharm Pract 2013, 26:464-475.
2. Bartlett J.G., Gerding D.N. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl. 1):S12-S18.
3. Centers for Disease C, Prevention Surveillance for community-associated Clostridium difficile-Connecticut, 2006 2008, vol. 57:340-343. MMWR Morb Mortal Wkly Rep.
4. Dumyati G., Stevens V., Hannett G.E., Thompson A.D., Long C., Maccannell D., et al. Community-associated Clostridium difficile infections, Monroe County, New York, USA. Emerg Infect Dis 2012, 18:392-400.
5. Lucado J., Gould C., Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009: statistical Brief #124, in Healthcare Cost and Utilization Project (HCUP) Statistical Briefs 2006, Rockville (MD).
6. Pepin J., Valiquette L., Alary M.E., Villemure P., Pelletier A., Forget K., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466-472.
7. Kuehne S.A., Cartman S.T., Heap J.T., Kelly M.L., Cockayne A., Minton N.P. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467:711-713.
8. Koon H.W., Shih D.Q., Hing T.C., Yoo J.H., Ho S., Chen X., et al. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes. Antimicrob Agents Chemother 2013, 57:3214-3223.
9. Pothoulakis C., Lamont J.T. Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Physiol Gastrointest Liver Physiol 2001, 280:G178-G183.
10. Madan R., Jr W.A. Immune responses to Clostridium difficile infection. Trends Mol Med 2012, 18:658-666.
11. McVey D.C., Vigna S.R. The role of leukotriene B4 in Clostridium difficile toxin A-induced ileitis in rats. Gastroenterology 2005, 128:1306-1316.
12. Pothoulakis C., Karmeli F., Kelly C.P., Eliakim R., Joshi M.A., O'Keane C.J., et al. Ketotifen inhibits Clostridium difficile toxin A-induced enteritis in rat ileum. Gastroenterology 1993, 105:701-707.
13. Peters-Golden M., Henderson W.R. Leukotrienes. N Engl J Med 2007, 357:1841-1854.
14. Sadik C.D., Luster A.D. Lipid-cytokine-chemokine cascades orchestrate leukocyte recruitment in inflammation. J Leukoc Biol 2012, 91:207-215.
15. Ford-Hutchinson A.W., Bray M.A., Doig M.V., Shipley M.E., Smith M.J., Leukotriene B. A potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980, 286:264-265.
16. Sharon P., Stenson W.F. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984, 86:453-460.
17. Rask-Madsen J., Bukhave K., Laursen L.S., Lauritsen K. 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Actions 1992, Spec No:C37-46.
18. Stanke-Labesque F., Pofelski J., Moreau-Gaudry A., Bessard G., Bonaz B. Urinary leukotriene E4 excretion: a biomarker of inflammatory bowel disease activity. Inflamm Bowel Dis 2008, 14:769-774.
19. Rocha M.F., Maia M.E., Bezerra L.R., Lyerly D.M., Guerrant R.L., Ribeiro R.A., et al. Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1beta, tumor necrosis factor alpha, and leukotrienes. Infect Immun 1997, 65:2740-2746.
20. Perez J., Springthorpe V.S., Sattar S.A. Clospore: a liquid medium for producing high titers of semi-purified spores of Clostridium difficile. J AOAC Int 2011, 94:618-626.
21. Theriot C.M., Koumpouras C.C., Carlson P.E., Bergin I.I., Aronoff D.M., Young V.B. Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. Gut Microbes 2011, 2:326-334.
22. Costa M.F., de Souza-Martins R., de Souza M.C., Benjamim C.F., Piva B., Diaz B.L., et al. Leukotriene B4 mediates gammadelta T lymphocyte migration in response to diverse stimuli. J Leukoc Biol 2010, 87:323-332.
23. Sforcin J.M., Nunes G.A., Missima F., Sa-Nunes A., Faccioli L.H. Effect of a leukotriene inhibitor (MK886) on nitric oxide and hydrogen peroxide production by macrophages of acutely and chronically stressed mice. J Pharm Pharmacol 2007, 59:1249-1254.
24. Reeves A.E., Koenigsknecht M.J., Bergin I.L., Young V.B. Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. Infect Immun 2012, 80:3786-3794.
25. Lawley T.D., Young V.B. Murine models to study Clostridium difficile infection and transmission. Anaerobe 2013, 24:94-97.
26. Theriot C.M., Koenigsknecht M.J., Carlson P.E., Hatton G.E., Nelson A.M., Li B., et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 2014, 5:3114.
27. Reeves A.E., Theriot C.M., Bergin I.L., Huffnagle G.B., Schloss P.D., Young V.B. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2011, 2:145-158.
28. Chae S., Eckmann L., Miyamoto Y., Pothoulakis C., Karin M., Kagnoff M.F. Epithelial cell I kappa B-kinase beta has an important protective role in Clostridium difficile toxin A-induced mucosal injury. J Immunol 2006, 177:1214-1220.
29. Jefferson K.K., Smith M.F., Bobak D.A. Roles of intracellular calcium and NF-kappa B in the Clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. J Immunol 1999, 163:5183-5191.
30. Ng J., Hirota S.A., Gross O., Li Y., Ulke-Lemee A., Potentier M.S., et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology 2010, 139. 542-52, 552 e1-3.
31. de Araujo Junqueira A.F., Dias A.A., Vale M.L., Spilborghs G.M., Bossa A.S., Lima B.B., et al. Adenosine deaminase inhibition prevents Clostridium difficile toxin A-induced enteritis in mice. Infect Immun 2011, 79:653-662.
32. Meyer G.K., Neetz A., Brandes G., Tsikas D., Butterfield J.H., Just I., et al. Clostridium difficile toxins A and B directly stimulate human mast cells. Infect Immun 2007, 75:3868-3876.
33. Ishida Y., Maegawa T., Kondo T., Kimura A., Iwakura Y., Nakamura S., et al. Essential involvement of IFN-gamma in Clostridium difficile toxin A-induced enteritis. J Immunol 2004, 172:3018-3025.
34. Kelly C.P., Becker S., Linevsky J.K., Joshi M.A., O'Keane J.C., Dickey B.F., et al. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest 1994, 93:1257-1265.
35. Soares E.M., Mason K.L., Rogers L.M., Serezani C.H., Faccioli L.H., Aronoff D.M. Leukotriene B4 enhances innate immune defense against the puerperal sepsis agent Streptococcus pyogenes. J Immunol 2013, 190:1614-1622.
36. Morato-Marques M., Campos M.R., Kane S., Rangel A.P., Lewis C., Ballinger M.N., et al. Leukotrienes target F-actin/cofilin-1 to enhance alveolar macrophage anti-fungal activity. J Biol Chem 2011, 286:28902-28913.
37. Chen M., Lam B.K., Kanaoka Y., Nigrovic P.A., Audoly L.P., Austen K.F., et al. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J Exp Med 2006, 203:837-842.
38. Trindade B.C., Sorgi C.A., Nicolete L.D., Malta T.M., Pinto M.T., Takayanagui O.M., et al. Leukotrienes are upregulated and associated with human T-lymphotropic virus type 1 (HTLV-1)-associated neuroinflammatory disease. PLoS One 2012, 7:e51873.
39. Peters-Golden M., Bailie M., Marshall T., Wilke C., Phan S.H., Toews G.B., et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002, 165:229-235.
40. Mazzon E., Sautebin L., Caputi A.P., Cuzzocrea S. 5-lipoxygenase modulates the alteration of paracellular barrier function in mice ileum during experimental colitis. Shock 2006, 25:377-383.
41. Cuzzocrea S., Rossi A., Mazzon E., Di Paola R., Genovese T., Muia C., et al. 5-Lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration. Lab Invest 2005, 85:808-822.
42. Burakoff R., Zhao L., Celifarco A.J., Rose K.L., Donovan V., Pothoulakis C., et al. Effects of purified Clostridium difficile toxin A on rabbit distal colon. Gastroenterology 1995, 109:348-354.
43. Lauritsen K., Laursen L.S., Bukhave K., Rask-Madsen J. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis. Gastroenterology 1988, 95:11-17.
44. Alcantara C., Stenson W.F., Steiner T.S., Guerrant R.L. Role of inducible cyclooxygenase and prostaglandins in Clostridium difficile toxin A-induced secretion and inflammation in an animal model. J Infect Dis 2001, 184:648-652.
45. Lima A.A., Nascimento N.R., Fang G.D., Yotseff P., Toyama M.H., Guerrant R.L., et al. Role of phospholipase A2 and tyrosine kinase in Clostridium difficile toxin A-induced disruption of epithelial integrity, histologic inflammatory damage and intestinal secretion. J Appl Toxicol 2008, 28:849-857.
46. Souza M.H., Melo-Filho A.A., Rocha M.F., Lyerly D.M., Cunha F.Q., Lima A.A., et al. The involvement of macrophage-derived tumour necrosis factor and lipoxygenase products on the neutrophil recruitment induced by Clostridium difficile toxin B. Immunology 1997, 91:281-288.
47. Peres C.M., de Paula L., Medeiros A.I., Sorgi C.A., Soares E.G., Carlos D., et al. Inhibition of leukotriene biosynthesis abrogates the host control of Mycobacterium tuberculosis. Microbes Infect 2007, 9:483-489.
48. Saiwai H., Ohkawa Y., Yamada H., Kumamaru H., Harada A., Okano H., et al. The LTB4-BLT1 axis mediates neutrophil infiltration and secondary injury in experimental spinal cord injury. Am J Pathol 2010, 176:2352-2366.
49. Kyne L., Warny M., Qamar A., Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000, 342:390-397.
50. Kyne L., Warny M., Qamar A., Kelly C.P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357:189-193.
51. Leav B.A., Blair B., Leney M., Knauber M., Reilly C., Lowy I., et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010, 28:965-969.
52. Babcock G.J., Broering T.J., Hernandez H.J., Mandell R.B., Donahue K., Boatright N., et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 2006, 74:6339-6347.
53. Giannasca P.J., Zhang Z.X., Lei W.D., Boden J.A., Giel M.A., Monath T.P., et al. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun 1999, 67:527-538.
54. Corthier G., Muller M.C., Wilkins T.D., Lyerly D., L'Haridon R. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun 1991, 59:1192-1195.
55. Gardiner D.F., Rosenberg T., Zaharatos J., Franco D., Ho D.D. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine 2009, 27:3598-3604.
56. Tager A.M., Bromley S.K., Medoff B.D., Islam S.A., Bercury S.D., Friedrich E.B., et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003, 4:982-990.
57. Spanbroek R., Hildner M., Steinhilber D., Fusenig N., Yoneda K., Radmark O., et al. 5-lipoxygenase expression in dendritic cells generated from CD34(+) hematopoietic progenitors and in lymphoid organs. Blood 2000, 96:3857-3865.
58. Medeiros A.I., Sa-Nunes A., Turato W.M., Secatto A., Frantz F.G., Sorgi C.A., et al. Leukotrienes are potent adjuvant during fungal infection: effects on memory T cells. J Immunol 2008, 181:8544-8551.